A new era in psoriasis and psoriatic arthritis therapy: new mechanisms of action and the introduction of biogeneric drugs

被引：1
作者：
Scheinberg, Morton [1 ,2 ]
机构：
[1] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil
[2] Hosp AACD, Ctr Pesquisas Clin, Sao Paulo, SP, Brazil
来源：
REVISTA BRASILEIRA DE REUMATOLOGIA | 2015年 / 55卷 / 06期
关键词：
DISEASE;
D O I：
10.1016/j.rbr.2015.09.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：469 / 470
页数：2
相关论文
共 12 条
  • [1] IL-17 targeted therapies for psoriasis
    Chiricozzi, Andrea
    Krueger, James G.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (08) : 993 - 1005
  • [2] Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital
    Golmia, Ricardo Prado
    Scheinberg, Morton Aaron
    [J]. EINSTEIN-SAO PAULO, 2013, 11 (04): : 492 - 494
  • [3] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    Griffiths, Christopher E. M.
    Reich, Kristian
    Lebwohl, Mark
    van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Cameron, Gregory S.
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta J.
    Ball, Susan
    Braun, Daniel K.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian J.
    Papp, Kim
    [J]. LANCET, 2015, 386 (9993) : 541 - 551
  • [4] Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
    Langley, Richard G.
    Elewski, Boni E.
    Lebwohl, Mark
    Reich, Kristian
    Griffiths, Christopher E. M.
    Papp, Kim
    Puig, Lluis
    Nakagawa, Hidemi
    Spelman, Lynda
    Sigurgeirsson, Bardur
    Rivas, Enrique
    Tsai, Tsen-Fang
    Wasel, Norman
    Tyring, Stephen
    Salko, Thomas
    Hampele, Isabelle
    Notter, Marianne
    Karpov, Alexander
    Helou, Silvia
    Papavassilis, Charis
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (04) : 326 - 338
  • [5] The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications
    Marinoni, Beatrice
    Ceribelli, Angela
    Massarotti, Marco S.
    Selmi, Carlo
    [J]. AUTOIMMUNITY HIGHLIGHTS, 2014, 5 (01) : 9 - 19
  • [6] Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
    Mease, Philip J.
    Genovese, Mark C.
    Greenwald, Maria W.
    Ritchlin, Christopher T.
    Beaulieu, Andre D.
    Deodhar, Atul
    Newmark, Richard
    Feng, JingYuan
    Erondu, Ngozi
    Nirula, Ajay
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (24) : 2295 - 2306
  • [7] Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
    Mease, Philip J.
    Armstrong, April W.
    [J]. DRUGS, 2014, 74 (04) : 423 - 441
  • [8] Mechanisms of Disease: Interleukin-17 and Type 17 Helper T Cells.
    Miossec, Pierre
    Korn, Thomas
    Kuchroo, Vijay K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (09) : 888 - 898
  • [9] Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, Sao Paulo, Brazil
    Scheinberg, Morton
    Goldenberg, Jose
    Feldman, Daniel P.
    Nobrega, Joao Luiz
    [J]. CLINICAL RHEUMATOLOGY, 2008, 27 (08) : 1049 - 1052
  • [10] Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
    Scheinberg, Morton
    Castaneda-Hernandez, Gilberto
    [J]. ARTHRITIS RESEARCH & THERAPY, 2014, 16 (06)
12